For children living with ulcerative colitis, treatment options are often limited, slow to work, or come with side effects that disrupt daily life. Parents are left navigating complex decisions, while kids may miss out on school, play, and the freedom to just feel like themselves. That’s what makes the results of this newly published clinical study so meaningful.
In the newly-published Prospective Pediatric Trial on the Safety and Effectiveness of CurQD® for Ulcerative Colitis in Pediatric Patients, researchers studied 20 children ages 4–17 who were newly diagnosed with mild-to-moderate UC and had never taken biologics or steroids. Within just 6 weeks on the CurQD® Protocol:
-
70% achieved clinical remission
-
50% reached biomarker remission
-
50% achieved “deep luminal remission”, meaning both symptom improvement and lower inflammation
These are more than just clinical numbers. For families, they represent the possibility of fewer sleepless nights, fewer emergency bathroom trips, and more normalcy—more childhood.
Pediatric IBD: A Growing Challenge
Pediatric IBD diagnoses are rising around the world, and children diagnosed early often face more aggressive disease and longer treatment timelines. Their needs are unique—not only medically, but emotionally and developmentally. Early, gentle, and effective support is critical to long-term well-being.
This isn’t the first time CurQD® has been explored in pediatric care. Previous observational use in leading children’s hospitals, including out of Los Angeles, has shown promise. But this new prospective trial adds a vital layer of controlled, clinical evidence to the growing body of research—and represents another step forward in validating CurQD® as part of a thoughtful, science-based approach for pediatric IBD.
A Natural Protocol with Clinical Rigor
The CurQD® Protocol combines time-tested botanicals—Qing Dai, turmeric, and more—developed under the guidance of leading IBD specialists. Even among children who experienced mild side effects, such as headaches or nausea, no serious adverse effects were reported. And importantly, no signs of pulmonary hypertension were detected by echocardiogram after six weeks of use.
For families looking for steroid-free options backed by real-world and clinical experience, this study reinforces the potential role of CurQD® in pediatric UC care—providing another reason to feel hopeful about the path ahead.
Evinature
